Lifecore Biomedical, Inc. (LFCR)
NASDAQ: LFCR · Real-Time Price · USD
5.61
-0.12 (-2.09%)
At close: Feb 21, 2025, 4:00 PM
5.71
+0.10 (1.78%)
After-hours: Feb 21, 2025, 7:08 PM EST
Lifecore Biomedical Revenue
Lifecore Biomedical had revenue of $32.56M in the quarter ending November 24, 2024, with 8.01% growth. This brings the company's revenue in the last twelve months to $130.86M, up 16.47% year-over-year. In the fiscal year ending May 26, 2024, Lifecore Biomedical had annual revenue of $128.26M with 24.20% growth.
Revenue (ttm)
$130.86M
Revenue Growth
+16.47%
P/S Ratio
1.35
Revenue / Employee
$249,729
Employees
524
Market Cap
207.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 26, 2024 | 128.26M | 24.99M | 24.20% |
| May 28, 2023 | 103.27M | -8.00M | -7.19% |
| May 29, 2022 | 111.27M | 10.40M | 10.31% |
| May 30, 2021 | 100.87M | -59.19M | -36.98% |
| May 31, 2020 | 160.07M | -397.49M | -71.29% |
| May 26, 2019 | Pro | Pro | Pro |
| May 27, 2018 | Pro | Pro | Pro |
| May 28, 2017 | Pro | Pro | Pro |
| May 29, 2016 | Pro | Pro | Pro |
| May 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
LFCR News
- 8 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out - Accesswire
- 9 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 10 days ago - Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 11 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Shareholders to Inquire about Securities Investigation - Accesswire
- 12 days ago - Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 13 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Connect - Accesswire
- 15 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation - Accesswire
- 16 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Investors to Learn More About the Investigation - Accesswire